Sign in
4

Changes in Ownership

ArriVent BioPharma, Inc. Filed Acc 0001104659-24-008799

Director bought 444,444 shares at $18.00 ($7,999,992)

  • Director acquired 2,582,884 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion +821,827 821,827 I
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion +821,827 821,827 I
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion +469,615 1,291,442 I
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion +469,615 1,291,442 I
ORBIMED ADVISORS LLC Director 2024-01-30 Purchase +222,222 $18.00 $3,999,996 1,513,664 I
ORBIMED ADVISORS LLC Director 2024-01-30 Purchase +222,222 $18.00 $3,999,996 1,513,664 I
Derivatives
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion · Series A Preferred Stock −821,827 0 I
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion · Series A Preferred Stock −821,827 0 I
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion · Series B Preferred Stock −469,615 0 I
ORBIMED ADVISORS LLC Director 2024-01-30 Conversion · Series B Preferred Stock −469,615 0 I
Open-market purchases · 444,444 sh · avg $18.00 · $7,999,992
Loading xslF345X05/tm244611-1_4seq1.xml…